The manufacturer of a new drug claims that it will lower
blood pressure by 13 points on the average. When the drug was
administered to 6 patients, the following drops in blood pressure
were registered: 12, 8, 15, 9, 10 and 16. Is the claim sustained at
the 0.05 level of significance.
Mean "\\mu" = "\\dfrac{12+8+15+9+10+16}{6}=\\dfrac{35}{3}"
Variance of population
"+(8-\\dfrac{35}{3})^2+(15-\\dfrac{35}{3})^2+(9-\\dfrac{35}{3})^2"
"+(10-\\dfrac{35}{3})^2+(16-\\dfrac{35}{3})^2)=\\dfrac{32}{3}"
"s=\\sqrt{s^2}=\\sqrt{\\dfrac{32}{3}}\\approx3.266"
The following null and alternative hypotheses need to be tested:
"H_0:\\mu=13"
"H_a:\\mu\\not=13"
This corresponds to a two-tailed test, for which a t-test for one mean, with unknown population standard deviation, using the sample standard deviation, will be used.
Based on the information provided, the significance level is "\\alpha = 0.05," "df=n-1=5" degrees of freedom, and the critical value for a two-tailed test is "t_c =2.570543."The rejection region for this two-tailed test is "R = \\{t:|t|> 2.570543\\}."
The t-statistic is computed as follows:
Since it is observed that "|t| = 0.9997<2.570543=t_c," it is then concluded that the null hypothesis is not rejected.
Using the P-value approach:
The p-value for two-tailed "df=5" degrees of freedom, "t=-0.9997" is "p=0.363349," and since "p=0.363349>0.05=\\alpha," it is concluded that the null hypothesis is not rejected.
Therefore, there is not enough evidence to claim that the population mean "\\mu" is different than 13, at the "\\alpha = 0.05" significance level.
Comments
Leave a comment